Lakhmir S. Chawla
CIK: 0001646626
Associated companies
Transaction History
| REVB | ▲ Buy | Grant | 32,011 | $0 | 8/17/2026 | View on chart |
| REVB | ▼ Sell | Tax Withholding | 2,261 | $4K | 2/3/2026 | View on chart |
| REVB | ▲ Buy | Grant | 41,981 | $38K | 1/8/2026 | View on chart |
| REVB | ▲ Buy | Grant | 15,625 | $20K | 10/29/2025 | View on chart |
| REVB | ▲ Buy | Grant | 181 | $700 | 2/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
REVB announces 1-for-7 reverse stock split effective Oct 20
Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.
REVB announces 1-for-7 reverse stock split effective Oct 20. Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.